🔗 Share this article

Given that America undertakes unprecedented changes to its vaccination schedules, an unexpected name appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by questioning Covid shots throughout the pandemic and has zeroed in on possible deaths after COVID-19 vaccination in her brief time at the FDA.

Proposed Shifts to Pediatric Vaccine Program

Agency leaders were set to announce major changes to the childhood immunization program earlier this month, aligning the US with the Danish vaccine program, it is understood – a substantial departure that would place the US out of step with much of the world with no evidence for public health gain. The planned update has been postponed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A New Direction at the Regulatory Body

The acting appointment may indicate a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Prasad strengthen their influence at the FDA – and it points to a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood immunization guidelines in the US in order to be more similar to the Danish model, a nation with universal health coverage and a population about the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on immunizations – usually the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Background

Høeg has no obvious background in pharmaceutical research, oversight or leadership, which has been customary for previous leaders of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in leading a sizeable institution. She has no expertise in drug approvals.”

Previous commissioners of CBER would “understand legal statutes and the underlying principles of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she lacks the sort of resume that prior appointees who headed CBER have had.”

The drug center has an immense portfolio at the agency, the former commissioner pointed out.

“Everybody just focuses on the innovative therapies, but the generic program clears numerous generic medications. There is also a biosimilars division, over-the-counter program and so forth, and each of these must be managed,” she noted. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant administrative aspect to the job, which supervises over 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” she said.

Agency Reaction and Controversial Initiatives

When asked about inquiries about Høeg’s qualifications and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a representative stated that the “inquiries are based on flawed presumptions”.

“Her resume matches the responsibilities of her position,” the spokesperson explained, citing the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a disputed one-day medication authorization process that allegedly worried her preceding directors. “How are these medications being chosen for this voucher program? Who takes the decisions?” Howard questioned. “There’s a lot of confidentiality going on at the agency right now.”

Overall, he said, “the FDA seems to be moving towards more relaxed oversight of most medications, with the exception of shots.”

Established Past Work on Vaccines

With immunizations, Dr. Høeg has a more documented, if problematic, history, Howard observe. She authored a analysis using non-validated crowd-sourced reports to estimate the rate of myocarditis after COVID-19 vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are riskier than they are.

Included in her “wish list” for the current government included revising regulations for novel immunizations and halting “non-essential” vaccines, she remarked post-election on a audio program. At the agency, Dr. Høeg has according to sources proposed preventing adolescent males from obtaining COVID-19 vaccinations.

“She’s an complete ideologue who begins with her conclusions and tailors the evidence to fit the science in a highly disingenuous, fraudulent fashion,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|